Holen Sie sich die Stockscreener-App
13.85
6.13%
0.80
Handel nachbörslich:
13.88
0.03
+0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$13.05
Offen:
$13.09
24-Stunden-Volumen:
5.06M
Relative Volume:
1.74
Marktkapitalisierung:
$2.76B
Einnahmen:
$3.90B
Nettoeinkommen (Verlust:
$-413.00M
KGV:
-6.6908
EPS:
-2.07
Netto-Cashflow:
$365.00M
1W Leistung:
+1.24%
1M Leistung:
-14.56%
6M Leistung:
-26.21%
1J Leistung:
-43.81%
1-Tages-Spanne:
$13.01
$14.00
1-Wochen-Bereich:
$12.52
$14.28
52-Wochen-Spanne:
$12.16
$27.48
Dentsply Sirona Inc Stock (XRAY) Company Profile
Firmenname
Dentsply Sirona Inc
Sektor
Telefon
844-546-3722
Adresse
13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC
Vergleichen Sie XRAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRAY
Dentsply Sirona Inc
|
13.85 | 2.60B | 3.90B | -413.00M | 365.00M | -2.07 |
|
ISRG
Intuitive Surgical Inc
|
482.35 | 171.42B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.96 | 55.88B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
86.48 | 42.55B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
288.28 | 41.48B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.22 | 17.25B | 2.90B | 467.20M | 306.90M | 6.37 |
Dentsply Sirona Inc Stock (XRAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-13 | Herabstufung | Needham | Buy → Hold |
| 2025-02-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-01-23 | Herabstufung | Jefferies | Buy → Hold |
| 2025-01-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-25 | Bestätigt | Needham | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-16 | Eingeleitet | Needham | Buy |
| 2023-11-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-12 | Hochstufung | William Blair | Underperform → Mkt Perform |
| 2022-08-05 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2022-06-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-04-19 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-08-06 | Bestätigt | Barrington Research | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-02 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-03-02 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-01-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-12-18 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-17 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-10-22 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-06-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-15 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-05-27 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-05-11 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-04-24 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-04-07 | Herabstufung | Goldman | Buy → Neutral |
| 2020-04-02 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-03-03 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-19 | Bestätigt | Stifel | Buy |
| 2019-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-02 | Hochstufung | Wellington Shields | Hold → Gradually Accumulate |
| 2019-07-26 | Eingeleitet | Evercore ISI | In-line |
| 2019-07-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Peer Perform |
Alle ansehen
Dentsply Sirona Inc Aktie (XRAY) Neueste Nachrichten
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - TradingView
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know | FinancialContent - FinancialContent
Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest
DENTSPLY SIRONA, Replimune Group, and Enovis Analysts Maintain Neutral Ratings - AInvest
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know | FinancialContent - FinancialContent
Dentsply Sirona Requests to Dismiss Class Action Filed by Investors - TradingView
Intraoral radiography market to hit US$ 2.7 billion by 2031 | Top - openPR.com
Understanding The Growth Of The Clear Aligners Market By 2035 - PharmiWeb.com
International Markets and Dentsply (XRAY): A Deep Dive for Investors - Yahoo Finance
DENTSPLY SIRONA outlines $80M annualized tariff headwind, maintains full-year outlook as new CEO signals accelerated transformation - MSN
Dentsply Sirona Reports Q2 Earnings Below Expectations, Maintains FY25 Outlook - AInvest
Dentsply Sirona (XRAY) Q2 Sales Drop 5% - AOL.com
Dentsply Sirona shares fall 1.59% intraday after UBS trims price target to $24. - AInvest
Dentsply Sirona shares fall 4.16% intraday as UBS lowers price target to $24. - AInvest
Why Dentsply International (XRAY) is a Top Growth Stock for the Long-Term - Yahoo Finance
UBS Trims Dentsply Sirona Price Target to $24 From $25, Maintains Buy Rating - MarketScreener
Dentsply Sirona price target lowered to $24 from $25 at UBS - TipRanks
Dentsply Sirona Reports Q2 2025 Financial Results - TipRanks
Dentsply Sirona Maintains Outlook Despite Sales Decline - AOL.com
DENTSPLY's Q2 2025 Earnings Call: Unpacking Contradictions in Tariffs, Orthodontics, and Customer Support - AInvest
Jefferies lowers Dentsply Sirona stock price target to $15 on tariff concerns - Investing.com Canada
Dentsply Sirona shares rise 1.66% after-hours following Q2 earnings call with adjusted earnings rise. - AInvest
DENTSPLY SIRONA: Hold Rating Maintained Amidst Mixed Performance and Promising Margin Improvements - TipRanks
Dentsply Sirona’s (NASDAQ:XRAY) Q2 Earnings Results: Revenue In Line With Expectations - Yahoo Finance
DENTSPLY SIRONA Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Dentsply Sirona Q2 2025 sees earnings beat, stock rises - Investing.com
DENTSPLY SIRONA Q2 2025 Earnings Call Transcript - MarketBeat
XRAY Stock Rises on Q2 Earnings & Revenues Beat, Adjusted Margins Up - Yahoo Finance
Deadline to Claim Your Payout from the $84M Dentsply Sirona Settlement Is in 2 Months - TradingView
Transcript : DENTSPLY SIRONA Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Dentsply (XRAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
DENTSPLY SIRONA Inc. SEC 10-Q Report - TradingView
DENTSPLY 2025 Q2 Earnings Deepened Losses Amid Revenue Decline - AInvest
Why DENTSPLY SIRONA Shares Are on a Rollercoaster - TipRanks
Dentsply Sirona Q2 Adjusted Earnings Rise, Revenue Falls; Maintains 2025 Guidance - MarketScreener
Dentsply Sirona Q2 net sales down 4.9% to $936mln, reaffirms FY25 outlook. - AInvest
Dentsply International (XRAY) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Dentsply Sirona Reports Second Quarter 2025 Results - TradingView
DENTSPLY SIRONA Inc. Declares Quarterly Cash Dividend, Payable on October 10, 2025 - MarketScreener
Dentsply Sirona beats Q2 earnings expectations despite overall decline By Investing.com - Investing.com Canada
Dentsply Sirona Posts Wider Loss In Q2 - Nasdaq
Dentsply Sirona Q2 2025 slides: Sales decline offset by margin expansion under new leadership - Investing.com South Africa
Earnings Preview: Dentsply Sirona - 富途牛牛
Join the 9th Annual MedDev eMarketing Summit in San Diego this August, featuring top digital marketing strategies and insights from industry giants like Philips and Dentsply Sirona. - AInvest
DENTSPLY SIRONA is Oversold - Nasdaq
Dental Laboratories Market Growth and Future Scope 2025-2032: - openPR.com
Dentsply Sirona (XRAY) Q2 Earnings Report Preview: What To Look For - Yahoo Finance
Dentsply Sirona, FDI, and Smile Train Expand Digital Cleft Care Education Resources - Orthodontic Products
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock? - MSN
Endodontics Devices Market: Analysis of Size, Shares, Business - openPR.com
Finanzdaten der Dentsply Sirona Inc-Aktie (XRAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):